MicroRNA Therapeutics in Cancer: Current Advances and Challenges
Abstract
:Simple Summary
Abstract
1. Introduction
2. Main Approaches for Therapeutic Targeting of miRNAs
3. Delivery Platforms for miRNA Therapeutics
4. Application of miRNA-Based Therapeutics in Selected Cancers
4.1. Lung Cancer
Cancer Type | miRNAs | Delivery System | MiRNA Loading Strategy | Cell Lines | Delivery Route In Vivo | Results | References |
---|---|---|---|---|---|---|---|
Lung cancer | miR-34a | Neutral Lipid Reagent (RNA-LANCEr II) | Encapsulation in phospholipid-oil emulsion | A549, BJ, NCI-H460, Calu-3, NCI-H596, NCI-H1650, HCC2935, SW-900, NCI-H226, NCI-H522, NCI-H1299, Wi-38 and TE353.sk | it, iv | Reduced cell proliferation and colony formation; Tumor growth inhibition | [77] |
miR-34 let-7 | Neutral Lipid Nanoemulsions | Encapsulation in phospholipid-oil emulsion | KRAS/TP53-mutated NSCLC cell lines: H358, H23, and H441 | iv | Decreased MET and MYC expression; 40% better survival rate | [78] | |
miR-29 | Cationic DOTMA Lipoplexes | Electrostatic interaction | A549 | iv | Decreased expression of miR-29b oncogenic targets DNMT3B, CDK6 and MCL1 | [82] | |
miR-16 | Bacterial Minicells (with EGFR antibody coating) | Loading via non-specific Porin channels | - | iv | Inhibition of tumor growth but dose-dependent toxicities | [83] | |
miR-145 | Liposomal Exosome-Mimetic Nanoplatforms (Integrin α6β4 coating) | Encapsulation in aqueous phase | A549 | ip, ro | Preferential accumulation at tumor sites | [74] | |
Liver cancer | miR-122 | Lentivirus | Viral vector expression system | Mahlavu SK-HEP-1 | sc | Reduced ADAM17 expression; Inhibition of tumor growth, angiogenesis, and intrahepatic metastasis | [84] |
Cationic Liposomes | Encapsulation | Sk-Hep-1 | it | 50% growth suppression of Sk-Hep-1 xenografts; impairment of angiogenesis; Downregulation of SRF, IGF1R and ADAM10 | [85] | ||
Anti-miR-221 | PEI-modified PLGA nanoparticles | Electrostatic interaction | HepG2 | sc | Inhibition of tumor growth; Increased circulating miR-221 | [86] | |
miR-199a/b-3p/anti-miR-10b | PEI-Cyclodextrin-PEG polymeric nanoparticles | Electrostatic interaction | Huh-7 PDX | iv | Inhibition of Huh-7 tumor growth by targeting mTOR, PAK4, RHOC and EMT pathways. Tumor suppression on PDX | [87] | |
miR-27a Sorafenib | Anti-GPC3 antibody-targeted lipid nanoparticles | Electrostatic interaction | HepG2 | - | Suppression of tumor burden; increased apoptosis | [88] | |
Breast cancer | miR-125a | Liposomes (with hyaluronic acid coating) | Electrostatic interaction | SKBR3, 21MT-1 | - | Reduced HER-2 expression | [89] |
miR-34a Doxorubicin | Hyaluronic acid- chitosan nanoparticles | Electrostatic interaction | MDA-MB-231 | iv | Enhanced response to chemotherapy | [90,91] | |
Anti-miR-21 Adriamycin | PEI graphene oxide nanocarriers | PEI-mediated electrostatic interaction | MCF-7 | - | Increased Adriamycin uptake | [92] | |
miR-9 miR-21 miR-145 | PEI-modified magnetic nanoparticles | Electrostatic interaction | MCF-7 | iv | Effective tumor targeting; Reduced tumor burden | [93] | |
miR-34 | Silica nanoparticles | Electrostatic interaction with added amine groups | Comma Dβ, SUM159pt | it | Inhibition of tumor growth | [94] | |
Glioblastoma | miR-100 anti-miR-21 | Gold-iron oxide nanoparticles (with T7 peptide-cyclodextrin-chitosan coating) | Electrostatic interaction | U87-MG | in | Diagnosis by MRI tracking of gold nanoparticles; Presensitization to temozolomide | [95] |
Anti-miR-21 | Cationic polyamine-co-ester | Electrostatic interaction | U87 | ced | Apoptosis of GBM cells; Better survival rates | [96] | |
miR-34a | Dendritic polyglycerolamine | Electrostatic interaction | Patient-derived GBM cells | iv | Reduced tumor burden | [97] | |
Thyroid cancer | Anti-miR-146 | Invivofectamine | Electrostatic interaction | Cal62 | it | Impaired tumor growth; Restored PTEN expression | [98] |
Anti-miR-21 | LNA | Chemical modifications | RTL-5 | sc | Inhibition of tumor growth | [99] | |
miR-204-5p | Lentivirus | Viral vector expression system | TCP-1 BCPAP | sc | Inhibition of tumor growth | [100] | |
Adrenocortical cancer | miR-7 | Bacterial Minicell particles “EnGeneIc Delivery Vehicles” (EDVs) (with EGFR antibody coating) | Loading via non-specific porin channels | NCI-H295R SW13 | iv | Inhibition of tumor growth by targeting CDK1/Raf1/mTOR signaling | [101] |
miR-431 Doxorubicin Mitotane | Lipofectamine | Electrostatic interaction | NCI-H295R | - | Reversed EMT phenotype | [102] | |
Ovarian cancer | miR-200c Paclitaxel | Lipofectamine | Electrostatic interaction | SCOV3 | - | Impaired migration and invasion, enhanced chemosensitivity | [103] |
miR-200a miR-141 | Lentivirus | Viral vector expression system | SCOV3 | - | Improved sensitivity to paclitaxel | [104] | |
miR-7 Paclitaxel | Polymeric Nanoparticles (monomethoxy(poly(ethylene glycol))-poly(d,l-lactide- co-glycolide)-poly(l-lysine) | Electrostatic interaction with the poly(l-lysine) chains in the core | SCOV3 | iv | Improved sensitivity to paclitaxel and apoptosis of cancer cells through inhibition of EGFR/ERK pathway | [105] | |
miR-15a miR-16 Cisplatin | Liposomes | Electrostatic interaction | A2780 A2780-CP20 OVCAR4 | iv | Reduced tumor burden; decreased expression of BMI1 oncogene and EMT markers | [106] | |
Anti-miR-21 | Mesoporous Silica Nanoparticles (with CGKRK peptide coating) | Calcium silicate trapping procedure | OAW42 | iv | Reduced tumor mass | [107] | |
Anti-miR-21 | Gold Nanoparticles | Surface functionalization with amine or thiol groups | - | - | Disrupted cell colony formation ability | [108] | |
miR-155 | PEI | Electrostatic interaction | OvCa-associated dendritic cells | ip | Boosted immunity and better survival | [109] | |
Prostate Cancer | miR-34a | Chitosan Nanoparticles | Electrostatic interaction via the protonated amino groups at low pH | PC3 | iv | Inhibited tumor growth and metastasis | [110] |
Anti-miR-221 | Mesoporous Silica Nanoparticles | Electrostatic interaction within the pore | PC3 | - | Less cancer expansion | [111] | |
miR-205 Docetaxel | Iron oxide nanoplatforms | Electrostatic interaction | PC3 C4-2 | - | Induced apoptosis and Chemosensitization | [112] | |
miR-145 | SSPEI with R11 peptide coating | Electrostatic interaction | PC3 LNCAP | iv | Impaired tumor growth Enhanced survival | [113] |
4.2. Liver Cancer
4.3. Breast Cancer
4.4. Glioblastoma
4.5. Endocrine Cancers
4.5.1. Thyroid Cancer
4.5.2. Adrenocortical Cancer
4.5.3. Ovarian Cancer
4.5.4. Prostate Cancer
5. Challenges in the Clinical Translation of miRNA Therapeutics
6. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Ambros, V. The functions of animal microRNAs. Nature 2004, 431, 350–355. [Google Scholar] [CrossRef]
- Ha, M.; Kim, V.N. Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell. Biol. 2014, 15, 509–524. [Google Scholar] [CrossRef]
- Leichter, A.L.; Sullivan, M.J.; Eccles, M.R.; Chatterjee, A. MicroRNA expression patterns and signalling pathways in the development and progression of childhood solid tumours. Mol. Cancer 2017, 16, 15. [Google Scholar] [CrossRef] [Green Version]
- Guo, Z.; Maki, M.; Ding, R.; Yang, Y.; Zhang, B.; Xiong, L. Genome-wide survey of tissue-specific microRNA and transcription factor regulatory networks in 12 tissues. Sci. Rep. 2014, 4, 5150. [Google Scholar] [CrossRef] [Green Version]
- Calin, G.A.; Dumitru, C.D.; Shimizu, M.; Bichi, R.; Zupo, S.; Noch, E.; Aldler, H.; Rattan, S.; Keating, M.; Rai, K.; et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 2002, 99, 15524–15529. [Google Scholar] [CrossRef] [Green Version]
- Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [Google Scholar] [CrossRef] [Green Version]
- Hata, A.; Kashima, R. Dysregulation of microRNA biogenesis machinery in cancer. Crit. Rev. Biochem. Mol. Biol. 2016, 51, 121–134. [Google Scholar] [CrossRef] [PubMed]
- Lin, S.; Gregory, R.I. MicroRNA biogenesis pathways in cancer. Nat. Rev. Cancer 2015, 15, 321–333. [Google Scholar] [CrossRef] [PubMed]
- Du, R.; Sun, W.; Xia, L.; Zhao, A.; Yu, Y.; Zhao, L.; Wang, H.; Huang, C.; Sun, S. Hypoxia-induced down-regulation of microRNA-34a promotes EMT by targeting the Notch signaling pathway in tubular epithelial cells. PLoS ONE 2012, 7, e30771. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Calin, G.A.; Croce, C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006, 6, 857–866. [Google Scholar] [CrossRef] [PubMed]
- Rupaimoole, R.; Calin, G.A.; Lopez-Berestein, G.; Sood, A.K. miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. Cancer Discov. 2016, 6, 235–246. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, H.; Yang, B.B. Friend or foe: The role of microRNA in chemotherapy resistance. Acta Pharmacol. Sin. 2013, 34, 870–879. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Si, W.; Shen, J.; Zheng, H.; Fan, W. The role and mechanisms of action of microRNAs in cancer drug resistance. Clin. Epigenet. 2019, 11, 25. [Google Scholar] [CrossRef] [PubMed]
- Yang, T.; Zheng, Z.M.; Li, X.N.; Li, Z.F.; Wang, Y.; Geng, Y.F.; Bai, L.; Zhang, X.B. MiR-223 modulates multidrug resistance via downregulation of ABCB1 in hepatocellular carcinoma cells. Exp. Biol. Med. 2013, 238, 1024–1032. [Google Scholar] [CrossRef]
- Bao, L.; Hazari, S.; Mehra, S.; Kaushal, D.; Moroz, K.; Dash, S. Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am. J. Pathol. 2012, 180, 2490–2503. [Google Scholar] [CrossRef] [Green Version]
- Kaehler, M.; Ruemenapp, J.; Gonnermann, D.; Nagel, I.; Bruhn, O.; Haenisch, S.; Ammerpohl, O.; Wesch, D.; Cascorbi, I.; Bruckmueller, H. MicroRNA-212/ABCG2-axis contributes to development of imatinib-resistance in leukemic cells. Oncotarget 2017, 8, 92018–92031. [Google Scholar] [CrossRef] [Green Version]
- Ning, F.L.; Wang, F.; Li, M.L.; Yu, Z.S.; Hao, Y.Z.; Chen, S.S. MicroRNA-182 modulates chemosensitivity of human non-small cell lung cancer to cisplatin by targeting PDCD4. Diagn. Pathol. 2014, 9, 143. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lei, L.; Huang, Y.; Gong, W. miR-205 promotes the growth, metastasis and chemoresistance of NSCLC cells by targeting PTEN. Oncol. Rep. 2013, 30, 2897–2902. [Google Scholar] [CrossRef] [Green Version]
- Levy, J.M.M.; Towers, C.G.; Thorburn, A. Targeting autophagy in cancer. Nat. Rev. Cancer 2017, 17, 528–542. [Google Scholar] [CrossRef] [PubMed]
- Zou, Z.; Wu, L.; Ding, H.; Wang, Y.; Zhang, Y.; Chen, X.; Chen, X.; Zhang, C.Y.; Zhang, Q.; Zen, K. MicroRNA-30a sensitizes tumor cells to cis-platinum via suppressing beclin 1-mediated autophagy. J. Biol. Chem. 2012, 287, 4148–4156. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tsuchiya, Y.; Nakajima, M.; Takagi, S.; Taniya, T.; Yokoi, T. MicroRNA Regulates the Expression of Human Cytochrome P450 1B1. Cancer Res. 2006, 66, 9090–9098. [Google Scholar] [CrossRef] [Green Version]
- Choi, Y.M.; An, S.; Lee, E.M.; Kim, K.; Choi, S.J.; Kim, J.S.; Jang, H.H.; An, I.S.; Bae, S. CYP1A1 is a target of miR-892a-mediated post-transcriptional repression. Int. J. Oncol. 2012, 41, 331–336. [Google Scholar] [PubMed] [Green Version]
- Ling, H.; Fabbri, M.; Calin, G.A. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat. Rev. Drug. Discov. 2013, 12, 847–865. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shah, M.Y.; Ferrajoli, A.; Sood, A.K.; Lopez-Berestein, G.; Calin, G.A. microRNA Therapeutics in Cancer—An Emerging Concept. EBioMedicine 2016, 12, 34–42. [Google Scholar] [CrossRef] [Green Version]
- Hanna, J.; Hossain, G.S.; Kocerha, J. The Potential for microRNA Therapeutics and Clinical Research. Front. Genet. 2019, 10, 478. [Google Scholar] [CrossRef] [Green Version]
- Rupaimoole, R.; Slack, F.J. MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat. Rev. Drug Discov. 2017, 16, 203–222. [Google Scholar] [CrossRef] [PubMed]
- Shu, J.; e Silva, B.V.R.; Gao, T.; Xu, Z.; Cui, J. Dynamic and Modularized MicroRNA Regulation and Its Implication in Human Cancers. Sci. Rep. 2017, 7, 13356. [Google Scholar] [CrossRef] [Green Version]
- Berindan-Neagoe, I.; Monroig Pdel, C.; Pasculli, B.; Calin, G.A. MicroRNAome genome: A treasure for cancer diagnosis and therapy. CA Cancer J. Clin. 2014, 64, 311–336. [Google Scholar] [CrossRef]
- Mattes, J.; Collison, A.; Foster, P.S. Emerging role of microRNAs in disease pathogenesis and strategies for therapeutic modulation. Curr. Opin. Mol. Ther. 2008, 10, 150–157. [Google Scholar]
- Aquino-Jarquin, G. Emerging Role of CRISPR/Cas9 Technology for MicroRNAs Editing in Cancer Research. Cancer Res. 2017, 77, 6812–6817. [Google Scholar] [CrossRef] [Green Version]
- Ebert, M.S.; Sharp, P.A. MicroRNA sponges: Progress and possibilities. RNA 2010, 16, 2043–2050. [Google Scholar] [CrossRef] [Green Version]
- Simonson, B.; Das, S. MicroRNA Therapeutics: The Next Magic Bullet? Mini Rev. Med. Chem. 2015, 15, 467–474. [Google Scholar] [CrossRef]
- Ma, L.; Young, J.; Prabhala, H.; Pan, E.; Mestdagh, P.; Muth, D.; Teruya-Feldstein, J.; Reinhardt, F.; Onder, T.T.; Valastyan, S.; et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat. Cell Biol. 2010, 12, 247–256. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yoshino, H.; Yonemori, M.; Miyamoto, K.; Tatarano, S.; Kofuji, S.; Nohata, N.; Nakagawa, M.; Enokida, H. microRNA-210-3p depletion by CRISPR/Cas9 promoted tumorigenesis through revival of TWIST1 in renal cell carcinoma. Oncotarget 2017, 8, 20881–20894. [Google Scholar] [CrossRef] [PubMed]
- Bader, A.G.; Brown, D.; Winkler, M. The promise of microRNA replacement therapy. Cancer Res. 2010, 70, 7027–7030. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Johnson, C.D.; Esquela-Kerscher, A.; Stefani, G.; Byrom, M.; Kelnar, K.; Ovcharenko, D.; Wilson, M.; Wang, X.; Shelton, J.; Shingara, J.; et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res. 2007, 67, 7713–7722. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kumar, M.S.; Erkeland, S.J.; Pester, R.E.; Chen, C.Y.; Ebert, M.S.; Sharp, P.A.; Jacks, T. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc. Natl. Acad. Sci. USA 2008, 105, 3903–3908. [Google Scholar] [CrossRef] [Green Version]
- He, L.; He, X.; Lowe, S.W.; Hannon, G.J. microRNAs join the p53 network--another piece in the tumour-suppression puzzle. Nat. Rev. Cancer 2007, 7, 819–822. [Google Scholar] [CrossRef] [Green Version]
- Chaudhary, V.; Jangra, S.; Yadav, N.R. Nanotechnology based approaches for detection and delivery of microRNA in healthcare and crop protection. J. Nanobiotechnol. 2018, 16, 40. [Google Scholar] [CrossRef] [Green Version]
- Juliano, R.; Bauman, J.; Kang, H.; Ming, X. Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol. Pharm. 2009, 6, 686–695. [Google Scholar] [CrossRef] [Green Version]
- Danhier, F.; Feron, O.; Préat, V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control Release 2010, 148, 135–146. [Google Scholar] [CrossRef]
- Shi, J.; Kantoff, P.W.; Wooster, R.; Farokhzad, O.C. Cancer nanomedicine: Progress, challenges and opportunities. Nat. Rev. Cancer 2017, 17, 20–37. [Google Scholar] [CrossRef]
- Fu, Y.; Chen, J.; Huang, Z. Recent progress in microRNA-based delivery systems for the treatment of human disease. ExRNA 2019, 1, 24. [Google Scholar] [CrossRef] [Green Version]
- Kasar, S.; Salerno, E.; Yuan, Y.; Underbayev, C.; Vollenweider, D.; Laurindo, M.F.; Fernandes, H.; Bonci, D.; Addario, A.; Mazzella, F.; et al. Systemic in vivo lentiviral delivery of miR-15a/16 reduces malignancy in the NZB de novo mouse model of chronic lymphocytic leukemia. Genes Immun. 2012, 13, 109–119. [Google Scholar] [CrossRef] [PubMed]
- Kota, J.; Chivukula, R.R.; O’Donnell, K.A.; Wentzel, E.A.; Montgomery, C.L.; Hwang, H.W.; Chang, T.C.; Vivekanandan, P.; Torbenson, M.; Clark, K.R.; et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009, 137, 1005–1017. [Google Scholar] [CrossRef] [Green Version]
- Boussif, O.; Lezoualc’h, F.; Zanta, M.A.; Mergny, M.D.; Scherman, D.; Demeneix, B.; Behr, J.P. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine. Proc. Natl. Acad. Sci. USA 1995, 92, 7297–7301. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ibrahim, A.F.; Weirauch, U.; Thomas, M.; Grünweller, A.; Hartmann, R.K.; Aigner, A. MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res. 2011, 71, 5214–5224. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cosco, D.; Cilurzo, F.; Maiuolo, J.; Federico, C.; Di Martino, M.T.; Cristiano, M.C.; Tassone, P.; Fresta, M.; Paolino, D. Delivery of miR-34a by chitosan/PLGA nanoplexes for the anticancer treatment of multiple myeloma. Sci. Rep. 2015, 5, 17579. [Google Scholar] [CrossRef] [Green Version]
- Zhang, L.; Lyer, A.K.; Yang, X.; Kobayashi, E.; Guo, Y.; Mankin, H.; Hornicek, F.J.; Amiji, M.M.; Duan, Z. Polymeric nanoparticle-based delivery of microRNA-199a-3p inhibits proliferation and growth of osteosarcoma cells. Int. J. Nanomed. 2015, 10, 2913–2924. [Google Scholar]
- Layek, B.; Singh, J. N-hexanoyl, N-octanoyl and N-decanoyl chitosans: Binding affinity, cell uptake, and transfection. Carbohydr. Polym. 2012, 89, 403–410. [Google Scholar] [CrossRef]
- Ding, Y.; Jiang, Z.; Saha, K.; Kim, C.S.; Kim, S.T.; Landis, R.F.; Rotello, V.M. Gold nanoparticles for nucleic acid delivery. Mol. Ther. 2014, 22, 1075–1083. [Google Scholar] [CrossRef] [Green Version]
- Ekin, A.; Karatas, O.F.; Culha, M.; Ozen, M. Designing a gold nanoparticle-based nanocarrier for microRNA transfection into the prostate and breast cancer cells. J. Gene Med. 2014, 16, 331–335. [Google Scholar] [CrossRef]
- Ghosh, R.; Singh, L.C.; Shohet, J.M.; Gunaratne, P.H. A gold nanoparticle platform for the delivery of functional microRNAs into cancer cells. Biomaterials 2013, 34, 807–816. [Google Scholar] [CrossRef]
- Pugazhendhi, A.; Edison, T.; Karuppusamy, I.; Kathirvel, B. Inorganic nanoparticles: A potential cancer therapy for human welfare. Int. J. Pharm. 2018, 539, 104–111. [Google Scholar] [CrossRef]
- Zhang, Y.; Wang, Z.; Gemeinhart, R.A. Progress in microRNA delivery. J. Control Release 2013, 172, 962–974. [Google Scholar] [CrossRef] [Green Version]
- Tivnan, A.; Orr, W.S.; Gubala, V.; Nooney, R.; Williams, D.E.; McDonagh, C.; Prenter, S.; Harvey, H.; Domingo-Fernández, R.; Bray, I.M.; et al. Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PLoS ONE 2012, 7, e38129. [Google Scholar] [CrossRef]
- Scheideler, M.; Vidakovic, I.; Prassl, R. Lipid nanocarriers for microRNA delivery. Chem. Phys. Lipids 2020, 226, 104837. [Google Scholar] [CrossRef]
- Cheng, X.; Lee, R.J. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery. Adv. Drug Deliv. Rev. 2016, 99, 129–137. [Google Scholar] [CrossRef] [PubMed]
- Hong, C.A.; Nam, Y.S. Functional nanostructures for effective delivery of small interfering RNA therapeutics. Theranostics 2014, 4, 1211–1232. [Google Scholar] [CrossRef] [PubMed]
- Hosokawa, S.; Tagawa, T.; Niki, H.; Hirakawa, Y.; Ito, N.; Nohga, K.; Nagaike, K. Establishment and evaluation of cancer-specific human monoclonal antibody GAH for targeting chemotherapy using immunoliposomes. Hybrid Hybridomics 2004, 23, 109–120. [Google Scholar] [CrossRef] [PubMed]
- Matsumura, Y.; Gotoh, M.; Muro, K.; Yamada, Y.; Shirao, K.; Shimada, Y.; Okuwa, M.; Matsumoto, S.; Miyata, Y.; Ohkura, H.; et al. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann. Oncol. 2004, 15, 517–525. [Google Scholar] [CrossRef] [PubMed]
- Yang, G.; Yin, B. Therapeutic effects of long-circulating miR-135a-containing cationic immunoliposomes against gallbladder carcinoma. Sci. Rep. 2017, 7, 5982. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, F.; Sun, Y.; Shi, J. Programmed death-ligand 1 monoclonal antibody-linked immunoliposomes for synergistic efficacy of miR-130a and oxaliplatin in gastric cancers. Nanomedicine 2019, 14, 1729–1744. [Google Scholar] [CrossRef] [PubMed]
- Kaur, I.P.; Bhandari, R.; Bhandari, S.; Kakkar, V. Potential of solid lipid nanoparticles in brain targeting. J. Control Release 2008, 127, 97–109. [Google Scholar] [CrossRef] [PubMed]
- Shi, S.; Han, L.; Deng, L.; Zhang, Y.; Shen, H.; Gong, T.; Zhang, Z.; Sun, X. Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression. J. Control Release 2014, 194, 228–237. [Google Scholar] [CrossRef]
- Küçüktürkmen, B.; Bozkır, A. Development and characterization of cationic solid lipid nanoparticles for co-delivery of pemetrexed and miR-21 antisense oligonucleotide to glioblastoma cells. Drug Dev. Ind. Pharm. 2018, 44, 306–315. [Google Scholar] [CrossRef]
- Yousefpour Marzbali, M.; Yari Khosroushahi, A. Polymeric micelles as mighty nanocarriers for cancer gene therapy: A review. Cancer Chemother. Pharmacol. 2017, 79, 637–649. [Google Scholar] [CrossRef]
- Mittal, A.; Chitkara, D.; Behrman, S.W.; Mahato, R.I. Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer. Biomaterials 2014, 35, 7077–7087. [Google Scholar] [CrossRef]
- Taylor, K.; Howard, C.B.; Jones, M.L.; Sedliarou, I.; MacDiarmid, J.; Brahmbhatt, H.; Munro, T.P.; Mahler, S.M. Nanocell targeting using engineered bispecific antibodies. MAbs 2015, 7, 53–65. [Google Scholar] [CrossRef]
- MacDiarmid, J.A.; Mugridge, N.B.; Weiss, J.C.; Phillips, L.; Burn, A.L.; Paulin, R.P.; Haasdyk, J.E.; Dickson, K.A.; Brahmbhatt, V.N.; Pattison, S.T.; et al. Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics. Cancer Cell 2007, 11, 431–445. [Google Scholar] [CrossRef] [Green Version]
- MacDiarmid, J.A.; Madrid-Weiss, J.; Amaro-Mugridge, N.B.; Phillips, L.; Brahmbhatt, H. Bacterially-derived nanocells for tumor-targeted delivery of chemotherapeutics and cell cycle inhibitors. Cell Cycle 2007, 6, 2099–2105. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Reid, G.; Pel, M.E.; Kirschner, M.B.; Cheng, Y.Y.; Mugridge, N.; Weiss, J.; Williams, M.; Wright, C.; Edelman, J.J.; Vallely, M.P.; et al. Restoring expression of miR-16: A novel approach to therapy for malignant pleural mesothelioma. Ann. Oncol. 2013, 24, 3128–3135. [Google Scholar] [CrossRef]
- Luan, X.; Sansanaphongpricha, K.; Myers, I.; Chen, H.; Yuan, H.; Sun, D. Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta Pharmacol. Sin. 2017, 38, 754–763. [Google Scholar] [CrossRef] [Green Version]
- Vazquez-Rios, A.J.; Molina-Crespo, A.; Bouzo, B.L.; Lopez-Lopez, R.; Moreno-Bueno, G.; de la Fuente, M. Exosome-mimetic nanoplatforms for targeted cancer drug delivery. J. Nanobiotechnol. 2019, 17, 85. [Google Scholar] [CrossRef] [Green Version]
- Bonneau, E.; Neveu, B.; Kostantin, E.; Tsongalis, G.J.; De Guire, V. How close are miRNAs from clinical practice? A perspective on the diagnostic and therapeutic market. EJIFCC 2019, 30, 114–127. [Google Scholar] [PubMed]
- Li, Y.L.; Liu, X.M.; Zhang, C.Y.; Zhou, J.B.; Shao, Y.; Liang, C.; Wang, H.M.; Hua, Z.Y.; Lu, S.D.; Ma, Z.L. MicroRNA-34a/EGFR axis plays pivotal roles in lung tumorigenesis. Oncogenesis 2017, 6, e372. [Google Scholar] [CrossRef] [Green Version]
- Wiggins, J.F.; Ruffino, L.; Kelnar, K.; Omotola, M.; Patrawala, L.; Brown, D.; Bader, A.G. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 2010, 70, 5923–5930. [Google Scholar] [CrossRef] [Green Version]
- Kasinski, A.L.; Kelnar, K.; Stahlhut, C.; Orellana, E.; Zhao, J.; Shimer, E.; Dysart, S.; Chen, X.; Bader, A.G.; Slack, F.J. A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer. Oncogene 2015, 34, 3547–3555. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cortez, M.A.; Valdecanas, D.; Zhang, X.; Zhan, Y.; Bhardwaj, V.; Calin, G.A.; Komaki, R.; Giri, D.K.; Quini, C.C.; Wolfe, T.; et al. Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer. Mol. Ther. 2014, 22, 1494–1503. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Beg, M.S.; Brenner, A.J.; Sachdev, J.; Borad, M.; Kang, Y.K.; Stoudemire, J.; Smith, S.; Bader, A.G.; Kim, S.; Hong, D.S. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Investig. New Drugs 2017, 35, 180–188. [Google Scholar] [CrossRef]
- Hong, D.S.; Kang, Y.K.; Borad, M.; Sachdev, J.; Ejadi, S.; Lim, H.Y.; Brenner, A.J.; Park, K.; Lee, J.L.; Kim, T.Y.; et al. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br. J. Cancer 2020, 122, 1630–1637. [Google Scholar] [CrossRef]
- Wu, Y.; Crawford, M.; Mao, Y.; Lee, R.J.; Davis, I.C.; Elton, T.S.; Lee, L.J.; Nana-Sinkam, S.P. Therapeutic Delivery of MicroRNA-29b by Cationic Lipoplexes for Lung Cancer. Mol. Ther. Nucleic Acids 2013, 2, e84. [Google Scholar] [CrossRef] [PubMed]
- van Zandwijk, N.; Pavlakis, N.; Kao, S.C.; Linton, A.; Boyer, M.J.; Clarke, S.; Huynh, Y.; Chrzanowska, A.; Fulham, M.J.; Bailey, D.L.; et al. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: A first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol. 2017, 18, 1386–1396. [Google Scholar] [CrossRef]
- Tsai, W.C.; Hsu, P.W.; Lai, T.C.; Chau, G.Y.; Lin, C.W.; Chen, C.M.; Lin, C.D.; Liao, Y.L.; Wang, J.L.; Chau, Y.P.; et al. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 2009, 49, 1571–1582. [Google Scholar] [CrossRef]
- Hsu, S.H.; Yu, B.; Wang, X.; Lu, Y.; Schmidt, C.R.; Lee, R.J.; Lee, L.J.; Jacob, S.T.; Ghoshal, K. Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor. Nanomedicine 2013, 9, 1169–1180. [Google Scholar] [CrossRef] [Green Version]
- Li, F.; Wang, F.; Zhu, C.; Wei, Q.; Zhang, T.; Zhou, Y.L. miR-221 suppression through nanoparticle-based miRNA delivery system for hepatocellular carcinoma therapy and its diagnosis as a potential biomarker. Int. J. Nanomed. 2018, 13, 2295–2307. [Google Scholar] [CrossRef] [Green Version]
- Shao, S.; Hu, Q.; Wu, W.; Wang, M.; Huang, J.; Zhao, X.; Tang, G.; Liang, T. Tumor-triggered personalized microRNA cocktail therapy for hepatocellular carcinoma. Biomater. Sci. 2020, 8, 6579–6591. [Google Scholar] [CrossRef]
- Wang, Z.; Zhao, K.; Zhang, Y.; Duan, X.; Zhao, Y. Anti-GPC3 Antibody Tagged Cationic Switchable Lipid-Based Nanoparticles for the Co-Delivery of Anti-miRNA27a And Sorafenib in Liver Cancers. Pharm. Res. 2019, 36, 145. [Google Scholar] [CrossRef] [PubMed]
- Hayward, S.L.; Francis, D.M.; Kholmatov, P.; Kidambi, S. Targeted Delivery of MicroRNA125a-5p by Engineered Lipid Nanoparticles for the Treatment of HER2 Positive Metastatic Breast Cancer. J. Biomed. Nanotechnol. 2016, 12, 554–568. [Google Scholar] [CrossRef] [PubMed]
- Deng, X.; Cao, M.; Zhang, J.; Hu, K.; Yin, Z.; Zhou, Z.; Xiao, X.; Yang, Y.; Sheng, W.; Wu, Y.; et al. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. Biomaterials 2014, 35, 4333–4344. [Google Scholar] [CrossRef]
- Imani, S.; Wu, R.C.; Fu, J. MicroRNA-34 family in breast cancer: From research to therapeutic potential. J. Cancer 2018, 9, 3765–3775. [Google Scholar] [CrossRef] [Green Version]
- Zhi, F.; Dong, H.; Jia, X.; Guo, W.; Lu, H.; Yang, Y.; Ju, H.; Zhang, X.; Hu, Y. Functionalized graphene oxide mediated adriamycin delivery and miR-21 gene silencing to overcome tumor multidrug resistance in vitro. PLoS ONE 2013, 8, e60034. [Google Scholar] [CrossRef] [Green Version]
- Yu, Y.; Yao, Y.; Yan, H.; Wang, R.; Zhang, Z.; Sun, X.; Zhao, L.; Ao, X.; Xie, Z.; Wu, Q. A Tumor-specific MicroRNA Recognition System Facilitates the Accurate Targeting to Tumor Cells by Magnetic Nanoparticles. Mol. Ther. Nucleic Acids 2016, 5, e318. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Panebianco, F.; Climent, M.; Malvindi, M.A.; Pompa, P.P.; Bonetti, P.; Nicassio, F. Delivery of biologically active miR-34a in normal and cancer mammary epithelial cells by synthetic nanoparticles. Nanomedicine 2019, 19, 95–105. [Google Scholar] [CrossRef]
- Sukumar, U.K.; Bose, R.J.C.; Malhotra, M.; Babikir, H.A.; Afjei, R.; Robinson, E.; Zeng, Y.; Chang, E.; Habte, F.; Sinclair, R.; et al. Intranasal delivery of targeted polyfunctional gold-iron oxide nanoparticles loaded with therapeutic microRNAs for combined theranostic multimodality imaging and presensitization of glioblastoma to temozolomide. Biomaterials 2019, 218, 119342. [Google Scholar] [CrossRef]
- Seo, Y.E.; Suh, H.W.; Bahal, R.; Josowitz, A.; Zhang, J.; Song, E.; Cui, J.; Noorbakhsh, S.; Jackson, C.; Bu, T.; et al. Nanoparticle-mediated intratumoral inhibition of miR-21 for improved survival in glioblastoma. Biomaterials 2019, 201, 87–98. [Google Scholar] [CrossRef] [PubMed]
- Ofek, P.; Calderón, M.; Mehrabadi, F.S.; Krivitsky, A.; Ferber, S.; Tiram, G.; Yerushalmi, N.; Kredo-Russo, S.; Grossman, R.; Ram, Z.; et al. Restoring the oncosuppressor activity of microRNA-34a in glioblastoma using a polyglycerol-based polyplex. Nanomedicine 2016, 12, 2201–2214. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ramirez-Moya, J.; Wert-Lamas, L.; Santisteban, P. MicroRNA-146b promotes PI3K/AKT pathway hyperactivation and thyroid cancer progression by targeting PTEN. Oncogene 2018, 37, 3369–3383. [Google Scholar] [CrossRef]
- Frezzetti, D.; Menna, M.D.; Zoppoli, P.; Guerra, C.; Ferraro, A.; Bello, A.M.; Luca, P.D.; Calabrese, C.; Fusco, A.; Ceccarelli, M.; et al. Upregulation of miR-21 by Ras in vivo and its role in tumor growth. Oncogene 2011, 30, 275–286. [Google Scholar] [CrossRef] [Green Version]
- Liu, L.; Wang, J.; Li, X.; Ma, J.; Shi, C.; Zhu, H.; Xi, Q.; Zhang, J.; Zhao, X.; Gu, M. miR-204-5p suppresses cell proliferation by inhibiting IGFBP5 in papillary thyroid carcinoma. Biochem. Biophys. Res. Commun. 2015, 457, 621–626. [Google Scholar] [CrossRef]
- Glover, A.R.; Zhao, J.T.; Gill, A.J.; Weiss, J.; Mugridge, N.; Kim, E.; Feeney, A.L.; Ip, J.C.; Reid, G.; Clarke, S.; et al. MicroRNA-7 as a tumor suppressor and novel therapeutic for adrenocortical carcinoma. Oncotarget 2015, 6, 36675–36688. [Google Scholar] [CrossRef] [Green Version]
- Kwok, G.T.Y.; Zhao, J.T.; Glover, A.R.; Gill, A.J.; Clifton-Bligh, R.; Robinson, B.G.; Ip, J.C.Y.; Sidhu, S.B. microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma. Oncologist 2019, 24, e241–e250. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Leskelä, S.; Leandro-García, L.J.; Mendiola, M.; Barriuso, J.; Inglada-Pérez, L.; Muñoz, I.; Martínez-Delgado, B.; Redondo, A.; Santiago, J.d.; Robledo, M.; et al. The miR-200 family controls β-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr. Relat. Cancer 2011, 18, 85–95. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mateescu, B.; Batista, L.; Cardon, M.; Gruosso, T.; de Feraudy, Y.; Mariani, O.; Nicolas, A.; Meyniel, J.P.; Cottu, P.; Sastre-Garau, X.; et al. miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat. Med. 2011, 17, 1627–1635. [Google Scholar] [CrossRef] [PubMed]
- Cui, X.; Sun, Y.; Shen, M.; Song, K.; Yin, X.; Di, W.; Duan, Y. Enhanced Chemotherapeutic Efficacy of Paclitaxel Nanoparticles Co-delivered with MicroRNA-7 by Inhibiting Paclitaxel-Induced EGFR/ERK pathway Activation for Ovarian Cancer Therapy. ACS Appl. Mater. Interfaces 2018, 10, 7821–7831. [Google Scholar] [CrossRef] [PubMed]
- Dwivedi, S.K.; Mustafi, S.B.; Mangala, L.S.; Jiang, D.; Pradeep, S.; Rodriguez-Aguayo, C.; Ling, H.; Ivan, C.; Mukherjee, P.; Calin, G.A.; et al. Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget 2016, 7, 15093–15104. [Google Scholar] [CrossRef] [PubMed]
- Bertucci, A.; Kim, K.H.; Kang, J.; Zuidema, J.M.; Lee, S.H.; Kwon, E.J.; Kim, D.; Howell, S.B.; Ricci, F.; Ruoslahti, E.; et al. Tumor-Targeting, MicroRNA-Silencing Porous Silicon Nanoparticles for Ovarian Cancer Therapy. ACS Appl. Mater. Interfaces 2019, 11, 23926–23937. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kafshdooz, L.; Pourfathi, H.; Akbarzadeh, A.; Kafshdooz, T.; Razban, Z.; Sheervalilou, R.; Ebrahimi Sadr, N.; Khalilov, R.; Saghfi, S.; Kavetskyy, T.; et al. The role of microRNAs and nanoparticles in ovarian cancer: A review. Artif. Cells Nanomed. Biotechnol. 2018, 46, 241–247. [Google Scholar] [CrossRef]
- Cubillos-Ruiz, J.R.; Baird, J.R.; Tesone, A.J.; Rutkowski, M.R.; Scarlett, U.K.; Camposeco-Jacobs, A.L.; Anadon-Arnillas, J.; Harwood, N.M.; Korc, M.; Fiering, S.N.; et al. Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer. Cancer Res. 2012, 72, 1683–1693. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gaur, S.; Wen, Y.; Song, J.H.; Parikh, N.U.; Mangala, L.S.; Blessing, A.M.; Ivan, C.; Wu, S.Y.; Varkaris, A.; Shi, Y.; et al. Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. Oncotarget 2015, 6, 29161–29177. [Google Scholar] [CrossRef] [Green Version]
- Farina, N.H.; Zingiryan, A.; Vrolijk, M.A.; Perrapato, S.D.; Ades, S.; Stein, G.S.; Lian, J.B.; Landry, C.C. Nanoparticle-based targeted cancer strategies for non-invasive prostate cancer intervention. J. Cell. Physiol. 2018, 233, 6408–6417. [Google Scholar] [CrossRef]
- Nagesh, P.K.B.; Chowdhury, P.; Hatami, E.; Boya, V.K.N.; Kashyap, V.K.; Khan, S.; Hafeez, B.B.; Chauhan, S.C.; Jaggi, M.; Yallapu, M.M. miRNA-205 Nanoformulation Sensitizes Prostate Cancer Cells to Chemotherapy. Cancers 2018, 10, 289. [Google Scholar] [CrossRef] [Green Version]
- Zhang, T.; Xue, X.; He, D.; Hsieh, J.-T. A prostate cancer-targeted polyarginine-disulfide linked PEI nanocarrier for delivery of microRNA. Cancer Lett. 2015, 365, 156–165. [Google Scholar] [CrossRef]
- Villanueva, A. Hepatocellular Carcinoma. N. Engl. J. Med. 2019, 380, 1450–1462. [Google Scholar] [CrossRef] [Green Version]
- Wang, X.; He, Y.; Mackowiak, B.; Gao, B. MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases. Gut 2021, 70, 784–795. [Google Scholar] [CrossRef]
- Schueller, F.; Roy, S.; Vucur, M.; Trautwein, C.; Luedde, T.; Roderburg, C. The Role of miRNAs in the Pathophysiology of Liver Diseases and Toxicity. Int. J. Mol. Sci. 2018, 19, 261. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, G.; Wang, Q.; Xu, R. Therapeutics Based on microRNA: A New Approach for Liver Cancer. Curr. Genomics 2010, 11, 311–325. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, H.; Chiu, M.; Xie, Z.; Chiu, M.; Liu, Z.; Chen, P.; Liu, S.; Byrd, J.C.; Muthusamy, N.; Garzon, R.; et al. Synthetic microRNA cassette dosing: Pharmacokinetics, tissue distribution and bioactivity. Mol. Pharm. 2012, 9, 1638–1644. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Baboci, L.; Capolla, S.; Di Cintio, F.; Colombo, F.; Mauro, P.; Dal Bo, M.; Argenziano, M.; Cavalli, R.; Toffoli, G.; Macor, P. The Dual Role of the Liver in Nanomedicine as an Actor in the Elimination of Nanostructures or a Therapeutic Target. J. Oncol. 2020, 2020, 4638192. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gramantieri, L.; Ferracin, M.; Fornari, F.; Veronese, A.; Sabbioni, S.; Liu, C.G.; Calin, G.A.; Giovannini, C.; Ferrazzi, E.; Grazi, G.L.; et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res. 2007, 67, 6092–6099. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jiang, J.; Gusev, Y.; Aderca, I.; Mettler, T.A.; Nagorney, D.M.; Brackett, D.J.; Roberts, L.R.; Schmittgen, T.D. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin. Cancer Res. 2008, 14, 419–427. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Meng, F.; Henson, R.; Wehbe-Janek, H.; Ghoshal, K.; Jacob, S.T.; Patel, T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133, 647–658. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hsieh, T.H.; Hsu, C.Y.; Tsai, C.F.; Long, C.Y.; Chai, C.Y.; Hou, M.F.; Lee, J.N.; Wu, D.C.; Wang, S.C.; Tsai, E.M. miR-125a-5p is a prognostic biomarker that targets HDAC4 to suppress breast tumorigenesis. Oncotarget 2015, 6, 494–509. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shi, L.; Chen, J.; Yang, J.; Pan, T.; Zhang, S.; Wang, Z. MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. Brain Res. 2010, 1352, 255–264. [Google Scholar] [CrossRef] [PubMed]
- Wang, G.; Wang, J.J.; Tang, H.M.; To, S.S. Targeting strategies on miRNA-21 and PDCD4 for glioblastoma. Arch. Biochem. Biophys. 2015, 580, 64–74. [Google Scholar] [CrossRef]
- Alrfaei, B.M.; Clark, P.; Vemuganti, R.; Kuo, J.S. MicroRNA miR-100 Decreases Glioblastoma Growth by Targeting SMARCA5 and ErbB3 in Tumor-Initiating Cells. Technol. Cancer Res. Treat. 2020, 19, 1533033820960748. [Google Scholar] [CrossRef] [PubMed]
- Lee, S.Y. Temozolomide resistance in glioblastoma multiforme. Genes Dis. 2016, 3, 198–210. [Google Scholar] [CrossRef] [Green Version]
- Pardini, B.; Calin, G.A. MicroRNAs and Long Non-Coding RNAs and Their Hormone-Like Activities in Cancer. Cancers 2019, 11, 378. [Google Scholar] [CrossRef] [Green Version]
- Peng, C.; Wang, Y.L. Editorial: MicroRNAs as New Players in Endocrinology. Front. Endocrinol. 2018, 9, 459. [Google Scholar] [CrossRef] [Green Version]
- Nikiforova, M.N.; Tseng, G.C.; Steward, D.; Diorio, D.; Nikiforov, Y.E. MicroRNA Expression Profiling of Thyroid Tumors: Biological Significance and Diagnostic Utility. J. Clin. Endocrinol. Metab. 2008, 93, 1600–1608. [Google Scholar] [CrossRef]
- Wojcicka, A.; Kolanowska, M.; Jazdzewski, K. Mechanisms in Endocrinology: MicroRNA in diagnostics and therapy of thyroid cancer. Eur. J. Endocrinol. 2016, 174, R89–R98. [Google Scholar] [CrossRef] [PubMed]
- Zhang, X.; Li, M.; Zuo, K.; Li, D.; Ye, M.; Ding, L.; Cai, H.; Fu, D.; Fan, Y.; Lv, Z. Upregulated miR-155 in Papillary Thyroid Carcinoma Promotes Tumor Growth by Targeting APC and Activating Wnt/β-Catenin Signaling. J. Clin. Endocrinol. Metab. 2013, 98, E1305–E1313. [Google Scholar] [CrossRef] [Green Version]
- Spitzweg, C.; Bible, K.C.; Hofbauer, L.C.; Morris, J.C. Advanced radioiodine-refractory differentiated thyroid cancer: The sodium iodide symporter and other emerging therapeutic targets. Lancet Diabetes Endocrinol. 2014, 2, 830–842. [Google Scholar] [CrossRef]
- Riesco-Eizaguirre, G.; Wert-Lamas, L.; Perales-Patón, J.; Sastre-Perona, A.; Fernández, L.P.; Santisteban, P. The miR-146b-3p/PAX8/NIS Regulatory Circuit Modulates the Differentiation Phenotype and Function of Thyroid Cells during Carcinogenesis. Cancer Res. 2015, 75, 4119–4130. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fassnacht, M.; Dekkers, O.M.; Else, T.; Baudin, E.; Berruti, A.; de Krijger, R.; Haak, H.R.; Mihai, R.; Assie, G.; Terzolo, M. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur. J. Endocrinol. 2018, 179, G1–G46. [Google Scholar] [CrossRef]
- Veytsman, I.; Nieman, L.; Fojo, T. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J. Clin. Oncol. 2009, 27, 4619–4629. [Google Scholar] [CrossRef]
- Fassnacht, M.; Terzolo, M.; Allolio, B.; Baudin, E.; Haak, H.; Berruti, A.; Welin, S.; Schade-Brittinger, C.; Lacroix, A.; Jarzab, B.; et al. Combination chemotherapy in advanced adrenocortical carcinoma. N. Engl. J. Med. 2012, 366, 2189–2197. [Google Scholar] [CrossRef] [PubMed]
- Assie, G.; Letouze, E.; Fassnacht, M.; Jouinot, A.; Luscap, W.; Barreau, O.; Omeiri, H.; Rodriguez, S.; Perlemoine, K.; Rene-Corail, F.; et al. Integrated genomic characterization of adrenocortical carcinoma. Nat. Genet. 2014, 46, 607–612. [Google Scholar] [CrossRef] [PubMed]
- Zheng, S.; Cherniack, A.D.; Dewal, N.; Moffitt, R.A.; Danilova, L.; Murray, B.A.; Lerario, A.M.; Else, T.; Knijnenburg, T.A.; Ciriello, G.; et al. Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell 2016, 30, 363. [Google Scholar] [CrossRef] [PubMed]
- Chabre, O.; Libe, R.; Assie, G.; Barreau, O.; Bertherat, J.; Bertagna, X.; Feige, J.J.; Cherradi, N. Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients. Endocr. Relat. Cancer 2013, 20, 579–594. [Google Scholar] [CrossRef]
- Igaz, P.; Igaz, I.; Nagy, Z.; Nyírő, G.; Szabó, P.M.; Falus, A.; Patócs, A.; Rácz, K. MicroRNAs in adrenal tumors: Relevance for pathogenesis, diagnosis, and therapy. Cell. Mol. Life Sci. 2015, 72, 417–428. [Google Scholar] [CrossRef] [PubMed]
- Özata, D.M.; Caramuta, S.; Velázquez-Fernández, D.; Akçakaya, P.; Xie, H.; Höög, A.; Zedenius, J.; Bäckdahl, M.; Larsson, C.; Lui, W.O. The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. Endocr. Relat. Cancer 2011, 18, 643–655. [Google Scholar] [CrossRef] [Green Version]
- Patterson, E.E.; Holloway, A.K.; Weng, J.; Fojo, T.; Kebebew, E. MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer 2011, 117, 1630–1639. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Singh, P.; Soon, P.S.; Feige, J.J.; Chabre, O.; Zhao, J.T.; Cherradi, N.; Lalli, E.; Sidhu, S.B. Dysregulation of microRNAs in adrenocortical tumors. Mol. Cell. Endocrinol. 2012, 351, 118–128. [Google Scholar] [CrossRef]
- Soon, P.S.; Tacon, L.J.; Gill, A.J.; Bambach, C.P.; Sywak, M.S.; Campbell, P.R.; Yeh, M.W.; Wong, S.G.; Clifton-Bligh, R.J.; Robinson, B.G.; et al. miR-195 and miR-483-5p Identified as Predictors of Poor Prognosis in Adrenocortical Cancer. Clin. Cancer Res. 2009, 15, 7684–7692. [Google Scholar] [CrossRef] [Green Version]
- Cherradi, N. microRNAs as Potential Biomarkers in Adrenocortical Cancer: Progress and Challenges. Front. Endocrinol. 2015, 6, 195. [Google Scholar] [CrossRef] [Green Version]
- Kalinowski, F.C.; Giles, K.M.; Candy, P.A.; Ali, A.; Ganda, C.; Epis, M.R.; Webster, R.J.; Leedman, P.J. Regulation of epidermal growth factor receptor signaling and erlotinib sensitivity in head and neck cancer cells by miR-7. PLoS ONE 2012, 7, e47067. [Google Scholar] [CrossRef]
- Jung, S.; Nagy, Z.; Fassnacht, M.; Zambetti, G.; Weiss, M.; Reincke, M.; Igaz, P.; Beuschlein, F.; Hantel, C. Preclinical progress and first translational steps for a liposomal chemotherapy protocol against adrenocortical carcinoma. Endocr. Relat. Cancer 2016, 23, 825–837. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Koutsaki, M.; Libra, M.; Spandidos, D.A.; Zaravinos, A. The miR-200 family in ovarian cancer. Oncotarget 2017, 8, 66629–66640. [Google Scholar] [CrossRef] [Green Version]
- Lü, J.M.; Liang, Z.; Wang, X.; Gu, J.; Yao, Q.; Chen, C. New polymer of lactic-co-glycolic acid-modified polyethylenimine for nucleic acid delivery. Nanomedicine 2016, 11, 1971–1991. [Google Scholar] [CrossRef] [Green Version]
- Rodriguez, A.; Vigorito, E.; Clare, S.; Warren, M.V.; Couttet, P.; Soond, D.R.; van Dongen, S.; Grocock, R.J.; Das, P.P.; Miska, E.A.; et al. Requirement of microRNA-155 for Normal Immune Function. Science 2007, 316, 608–611. [Google Scholar] [CrossRef] [Green Version]
- Zhang, S.; Cheng, Z.; Wang, Y.; Han, T. The Risks of miRNA Therapeutics: In a Drug Target Perspective. Drug Des. Dev. Ther. 2021, 15, 721–733. [Google Scholar] [CrossRef] [PubMed]
- Mullard, A. 2018 FDA drug approvals. Nat. Rev. Drug Discov. 2019, 18, 85–89. [Google Scholar] [CrossRef] [PubMed]
- Mullard, A. 2019 FDA drug approvals. Nat. Rev. Drug Discov. 2020, 19, 79–84. [Google Scholar] [CrossRef]
- Janssen, H.L.; Reesink, H.W.; Lawitz, E.J.; Zeuzem, S.; Rodriguez-Torres, M.; Patel, K.; van der Meer, A.J.; Patick, A.K.; Chen, A.; Zhou, Y.; et al. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 2013, 368, 1685–1694. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lindow, M.; Kauppinen, S. Discovering the first microRNA-targeted drug. J. Cell Biol. 2012, 199, 407–412. [Google Scholar] [CrossRef]
- van der Ree, M.H.; van der Meer, A.J.; van Nuenen, A.C.; de Bruijne, J.; Ottosen, S.; Janssen, H.L.; Kootstra, N.A.; Reesink, H.W. Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA-122 levels without affecting other microRNAs in plasma. Aliment. Pharmacol. Ther. 2016, 43, 102–113. [Google Scholar] [CrossRef] [Green Version]
- Shi, Y.; van der Meel, R.; Chen, X.; Lammers, T. The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy. Theranostics 2020, 10, 7921–7924. [Google Scholar] [CrossRef]
- Sindhwani, S.; Syed, A.M.; Ngai, J.; Kingston, B.R.; Maiorino, L.; Rothschild, J.; MacMillan, P.; Zhang, Y.; Rajesh, N.U.; Hoang, T.; et al. The entry of nanoparticles into solid tumours. Nat. Mater. 2020, 19, 566–575. [Google Scholar] [CrossRef] [PubMed]
- Blanco, E.; Shen, H.; Ferrari, M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol. 2015, 33, 941–951. [Google Scholar] [CrossRef]
- Haute, D.V.; Berlin, J.M. Challenges in realizing selectivity for nanoparticle biodistribution and clearance: Lessons from gold nanoparticles. Ther. Deliv. 2017, 8, 763–774. [Google Scholar] [CrossRef]
- Elmén, J.; Lindow, M.; Schütz, S.; Lawrence, M.; Petri, A.; Obad, S.; Lindholm, M.; Hedtjärn, M.; Hansen, H.F.; Berger, U.; et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008, 452, 896–899. [Google Scholar] [CrossRef] [PubMed]
- Krützfeldt, J.; Rajewsky, N.; Braich, R.; Rajeev, K.G.; Tuschl, T.; Manoharan, M.; Stoffel, M. Silencing of microRNAs in vivo with ‘antagomirs’. Nature 2005, 438, 685–689. [Google Scholar] [CrossRef]
- Zarin, D.A.; Tse, T.; Williams, R.J.; Califf, R.M.; Ide, N.C. The ClinicalTrials.gov results database—Update and key issues. N. Engl. J. Med. 2011, 364, 852–860. [Google Scholar] [CrossRef] [Green Version]
- Sainz, V.; Conniot, J.; Matos, A.I.; Peres, C.; Zupancic, E.; Moura, L.; Silva, L.C.; Florindo, H.F.; Gaspar, R.S. Regulatory aspects on nanomedicines. Biochem. Biophys. Res. Commun. 2015, 468, 504–510. [Google Scholar] [CrossRef] [PubMed]
- Hare, J.I.; Lammers, T.; Ashford, M.B.; Puri, S.; Storm, G.; Barry, S.T. Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. Adv. Drug. Deliv. Rev. 2017, 108, 25–38. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Monroig-Bosque Pdel, C.; Rivera, C.A.; Calin, G.A. MicroRNAs in cancer therapeutics: “from the bench to the bedside”. Expert Opin. Biol. Ther. 2015, 15, 1381–1385. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nanomedicine and the COVID-19 vaccines. Nature Nanotechnol. 2020, 15, 963. [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Reda El Sayed, S.; Cristante, J.; Guyon, L.; Denis, J.; Chabre, O.; Cherradi, N. MicroRNA Therapeutics in Cancer: Current Advances and Challenges. Cancers 2021, 13, 2680. https://doi.org/10.3390/cancers13112680
Reda El Sayed S, Cristante J, Guyon L, Denis J, Chabre O, Cherradi N. MicroRNA Therapeutics in Cancer: Current Advances and Challenges. Cancers. 2021; 13(11):2680. https://doi.org/10.3390/cancers13112680
Chicago/Turabian StyleReda El Sayed, Soha, Justine Cristante, Laurent Guyon, Josiane Denis, Olivier Chabre, and Nadia Cherradi. 2021. "MicroRNA Therapeutics in Cancer: Current Advances and Challenges" Cancers 13, no. 11: 2680. https://doi.org/10.3390/cancers13112680
APA StyleReda El Sayed, S., Cristante, J., Guyon, L., Denis, J., Chabre, O., & Cherradi, N. (2021). MicroRNA Therapeutics in Cancer: Current Advances and Challenges. Cancers, 13(11), 2680. https://doi.org/10.3390/cancers13112680